Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response

• US 6,581,606 B2
• Filed: 03/26/2001
• Issued: 06/24/2003
• Est. Priority Date: 07/06/1999
• Status: Expired due to Term

• Current Assignee: Dimensional Dosing Systems Incorporated
• Original Assignee: The Rx Files Corporation
• Inventors: Singer, Michaeal G., Kutzko, John D., McMichael, John P.
• Primary Examiner(s): Lacyk, John P.
• Application Number:
  US09/817,906
• Publication Number:
  US 20010018919A1
• Time in Patent Office: 820 Days
• Field of Search: 128/897-98, 600/300, 600/308, 600/347, 600/364-66, 600/368
• US Class Current: 128/898
• CPC Class Codes: A61B 17/00 Surgical instruments, devices or methods, e.g. tourniquets A61B18/00 takes precedence; contraceptive devices, pessaries, or applicators therefor A61F6/00; eye surgery A61F9/007; ear surgery A61F11/00
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 70/20 relating to practices or guidelines

Abstract

A method, apparatus and system for use in treating a patient receiving an antineoplastic drug to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the antineoplastic drug to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the antineoplastic drug'"'"'s action. Given the effectiveness of the antineoplastic drug'"'"'s action relative to the surrogate markers, a change in antineoplastic drug dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the antineoplastic drug dose change on the surrogate markers.

Claims

1. A method for calculating a revised dose of an antineoplastic drug for a patient using said antineoplastic drug, comprising the steps of:

accepting as a first input the patient'"'"'s current antineoplastic drug dose;

accepting as a second input a maximum dose of the antineoplastic drug;

accepting as a third input a percent response of the patient based on one or more surrogate markers used to monitor said antineoplastic drug; and

determining a revised dose, wherein said revised dose is a function of said current dose minus a ratio of the percent response of the patient and a ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.

2. The method of claim 1, wherein:

said determining step includes determining said revised dose based on the equation

3. The method of claim 1, wherein:

said antineoplastic drug is selected from a group comprising;

chemotherapeutic agents;

drugs which have an antineoplastic effect, but which are not normally classified as chemotherapeutic agents including, warfarin, heparin, minocycline, Vioxx, Celebrex, etc.;

drugs which have an antineoplastic effect that are currently in Phase I, II and/or III trials;

epothilones, analogs of epothilones, and their class of compounds;

meiphalan (Alkeran), carmustine {BCNU} (BiCNU), busulfan (Busulfex), lomustine {CCNU} (CeeNU), cyclophosphamide (Cytoxan), dacarbazine (DTIC-Dome), polifeprosan 20 with carmustine implant (Giladel), sterile ifosfamide (Ifex), chlorambucil (Leuderan), mechlorethamine (Mustargen), busulfan (Myleran), cyclophosphamide (Neosar), carboplatin (Paraplatin), cisplatin (Platinol), thiotepa (Thioplex), capecitabine (Xeloda), streptozocin (Zanosar), bicalutamide (Casodex), flutamide (Eulexin), leuprolide acetate (Lupron), nilutamide (Nilandron), leuprolide acetate (Viadur), doxorubicin hydrochloride (Adriamycin), bleomycin sulfate (Blenoxane), daunorubicin hydrochloride (Cerubidine), dactinomycin (Cosmegen), daunorubicin citrate liposome injection (DaunoXome), doxorubicin hydrochloride liposome injection (Doxil), epirubicin hydrochloride (Ellence), idarubicin hydrochloride (Idamycin), mitomycin (Mutamycin) doxorubicin (Rubex), valrubicin (Valstar), anastrozole (Arimidex), toremifene citrate (nolvadex), fluorouracil (Adrucil), cytarabine (Cyttosar-U), fluorouracil (Efudex), fludarabine (Fludara), (Fluorouracil), floxuridine (FUDR), interferon alfa-2b, recombinant (Intron A), Immunex (Methotrexate), plicamycin (Mithracin), mercaptopurine (Purinethol), methotrexate (Rheumatrex), interferon alfa-2a, recombinant (Roferon-A (Thioguanine), medroxyprogersterone acetate (Depo-Provera), estramustine phosphate sodium (Emcyt), estradiol (Estrace), leuprolide acetate (Lupron), megestrol acetate (Megace), octreotide acetate (Sandostatin), octreotide acetate for injection suspension (Sandostatin LAR), diethylstilbestrol diphosphate (Stilphostrol), testolactone (Teslac), goserelin acetate (Zoladex), etoposide phosphate (Etopophos), vincristine sulfate (Oncovin), etoposide (Toposar), vinblastine (Velban), etoposide (VePesid), vincristine sulfate (Vincasar PFS), teniposide (Vumon), trastuzumab (Herceptin), gemtuzumab ozogamiem (Mylotarg), rituximab (Rituxan), exemestane (Aromasin), irinotecan hydrocholoride (Camptosar), asparaginase (Elspar), gemcitabine hydrochloride (Gemzar), altretamine (Hexalen), topotecan hydrochloride (Hycamtin), hydroxyurea (Hydrea), (Leucovorin calcium), cladribine (Leustatin), mitotate (Lysodren) procarbazine hydrochloride, (Matulane), vinorelbine tartrate (Navelbine), pentrostatin sodium (Nipent), mitoxantrone (Novantrone), pegaspargase (Oncaspar), denileukin diftitix (Ontak), altretinoin (Panretin), porfimer (Photofrin), bexarotene (Targretin, bexarotene (Targretin Gel), paclitaxel (Taxol), docetaxel (Taxotere), temozolomide (Temodar), bacillus of Calmette and Guerin (Theracys BCG Live), arsenic trioxide (Trisenox), tretinoin (Vesanoid);

substances which foster anti-tumor activity; and

all substances derived from and/or related to the foregoing substances.

4. A method for calculating a revised dose of a antineoplastic drug for a patient using said antineoplastic drug, comprising the steps of:

accepting as a first input the patient'"'"'s current antineoplastic drug dose;

accepting as a second input the maximum dose of the antineoplastic drug;

accepting as a third input one or more numerical markers indicating a response of the patient to said antineoplastic drug; and

calculating said revised dose, wherein said revised dose is a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.

5. The method of claim 4, wherein:

said calculating step includes calculating said revised dose based on the equation

6. The method of claim 4, wherein:

said antineoplastic drug is selected from a group comprising;

chemotherapeutic agents;

drugs which have an antineoplastic effect, but which are not normally classified as chemotherapeutic agents including, warfarin, heparin, minocycline, Vioxx, Celebrex, etc.;

drugs which have an antineoplastic effect that are currently in Phase I, II and/or III trials;

epothilones, analogs of epothilones, and their class of compounds;

melphalan (Alkeran), carmustine {BCNU} (BiCNU), busulfan (Busulfex), lomustine {CCNU} (CeeNU), cyclophosphamide (Cytoxan), dacarbazine (DTIC-Dome), polifeprosan 20 with carmustine implant (Giladel), sterile ifosfamide (Ifex), chlorambucil (Leuderan), mechlorethamine (Mustargen), busulfan (Myleran), cyclophosphamide (Neosar), carboplatin (Paraplatin), cisplatin (Platinol), thiotepa (Thioplex), capecitabine (Xeloda), streptozocin (Zanosar), bicalutamide (Casodex), flutamide (Eulexin), leuprolide acetate (Lupron), nilutamide (Nilandron), leuprolide acetate (Viadur), doxorubicin hydrochloride (Adriamycin), bleomycin sulfate (Blenoxane), daunorubicin hydrochloride (Cerubidine), dactinomycin (Cosmegen), daunorubicin citrate liposome injection (DaunoXome), doxorubicin hydrochloride liposome injection (Doxil), epirubicin hydrochloride (Ellence), idarubicin hydrochloride (Idamycin), mitomycin (Mutamycin) doxorubicin (Rubex), valrubicin (Valstar), anastrozole (Arimidex), toremifene citrate (nolvadex), fluorouracil (Adrucil), cytarabine (Cyttosar-U), fluorouracil (Efudex), fludarabine (Fludara), (Fluorouracil), floxuridine (FUDR), interferon alfa-2b, recombinant (Intron A), Immunex (Methotrexate), plicamycin (Mithracin), mercaptopurine (Purinethol), methotrexate (Rheumatrex), interferon alfa-2a, recombinant (Roferon-A (Thioguanine), medroxyprogersterone acetate (Depo-Provera), estramustine phosphate sodium (Emcyt), estradiol (Estrace), leuprolide acetate (Lupron), megestrol acetate (Megace), octreotide acetate (Sandostatin), octreotide acetate for injection suspension (Sandostatin LAR), diethylstilbestrol diphosphate (Stilphostrol), testolactone (Teslac), goserelin acetate (Zoladex), etoposide phosphate (Etopophos), vincristine sulfate (Oncovin), etoposide (Toposar), vinblastine (Velban), etoposide (VePesid), vincristine sulfate (Vincasar PFS), teniposide (Vumon), trastuzumab (Herceptin), gemtuzumab ozogamicin (Mylotarg), rituximab (Rituxan), exemestane (Aromasin), irinotecan hydrocholoride (Camptosar), asparaginase (Elspar), gemcitabine hydrochloride (Gemzar), altretamine (Hexalen), topotecan hydrochloride (Hycamtin), hydroxyurea (Hydrea), (Leucovorin calcium), cladribine (Leustatin), mitotate (Lysodren) procarbazine hydrochloride, (Matulane), vinorelbine tartrate (Navelbine), pentrostatin sodium (Nipent), mitoxantrone (Novantrone), pegaspargase (Oncaspar), denileukin diftitix (Ontak), altretinoin (Panretin), porfimer (Photofrin), bexarotene (Targretin, bexarotene (Targretin Gel), paclitaxel (Taxol), docetaxel (Taxotere), temozolomide (Temodar), bacillus of Calmette and Guerin (Theracys BCG Live), arsenic trioxide (Trisenox), tretinoin (Vesanoid);

substances which foster anti-tumor activity; and

all substances derived from and/or related to the foregoing substances.

7. A method for determining a dose of a antineoplastic drug for a patient, comprising the steps of:

administering an initial dose of said antineoplastic drug to the patient;

evaluating the patient to monitor and characterize one or more numerical surrogate markers used for monitoring said antineoplastic drug;

determining, based on said numerical surrogate markers, if a dose change for said antineoplastic drug is necessary; and

calculating a revised dose as a function of said current dose minus the ratio of a percent response of the patient and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.

8. The method of claim 7, wherein:

said antineoplastic drug is selected from a group comprising;

chemotherapeutic agents;

drugs which have an antineoplastic effect, but which are not normally classified as chemotherapeutic agents including, warfarin, heparin, minocycline, Vioxx, Celebrex, etc.;

drugs which have an antineoplastic effect that are currently in Phase I, II and/or III trials;

epothilones, analogs of epothilones, and their class of compounds;

melphalan (Alkeran), carmustine {BCNU} (BiCNU), busulfan (Busulfex), lomustine {CCNU} (CeeNU), cyclophosphamide (Cytoxan), dacarbazine (DTIC-Dome), polifeprosan 20 with carmustine implant (Giladel), sterile ifosfamide (Ifex), chlorambucil (Leuderan), mechlorethamine (Mustargen), busulfan (Myleran), cyclophosphamide (Neosar), carboplatin (Paraplatin), cisplatin (Platinol), thiotepa (Thioplex), capecitabine (Xeloda), streptozocin (Zanosar), bicalutamide (Casodex), flutamide (Eulexin), leuprolide acetate (Lupron), nilutamide (Nilandron), leuprolide acetate (Viadur), doxorubicin hydrochloride (Adriamycin), bleomycin sulfate (Blenoxane), daunorubicin hydrochloride (Cerubidine), dactinomycin (Cosmegen), daunorubicin citrate liposome injection (DaunoXome), doxorubicin hydrochloride liposome injection (Doxil), epirubicin hydrochloride (Ellence), idarubicin hydrochloride (Idamycin), mitomycin (Mutamycin) doxorubicin (Rubex), valrubicin (Valstar), anastrozole (Arimidex), toremifene citrate (nolvadex), fluorouracil (Adrucil), cytarabine (Cyttosar-U), fluorouracil (Efudex), fludarabine (Fludara), (Fluorouracil), floxuridine (FUDR), interferon alfa-2b, recombinant (Intron A), Immunex (Methotrexate), plicamycin (Mithracin), mercaptopurine (Purinethol), methotrexate (Rheumatrex), interferon alfa-2a, recombinant (Roferon-A (Thioguanine), medroxyprogersterone acetate (Depo-Provera), estramustine phosphate sodium (Emcyt), estradiol (Estrace), leuprolide acetate (Lupron), megestrol acetate (Megace), octreotide acetate (Sandostatin), octreotide acetate for injection suspension (Sandostatin LAR), diethylstilbestrol diphosphate (Stilphostrol), testolactone (Teslac), goserelin acetate (Zoladex), etoposide phosphate (Etopophos), vincristine sulfate (Oncovin), etoposide (Toposar), vinblastine (Velban), etoposide (VePesid), vincristine sulfate (Vincasar PFS), teniposide (Vumon), trastuzumab (Herceptin), gemtuzumab ozogamicin (Mylotarg), rituximab (Rituxan), exemestane (Aromasin), irinotecan hydrocholoride (Camptosar), asparaginase (Elspar), gemcitabine hydrochloride (Gemzar), altretamine (Hexalen), topotecan hydrochloride (Hycamtin), hydroxyurea (Hydrea), (Leucovorin calcium), cladribine (Leustatin), mitotate (Lysodren) procarbazine hydrochloride, (Matulane), vinorelbine tartrate (Navelbine), pentrostatin sodium (Nipent), mitoxantrone (Novantrone), pegaspargase (Oncaspar), denileukin diftitix (Ontak), altretinoin (Panretin), porfimer (Photo fin), bexarotene (Targretin, bexarotene (Targretin Gel), paclitaxel (Taxol), docetaxel (Taxotere), temozolomide (Temodar), bacillus of Calmette and Guerin (Theracys BCG Live), arsenic trioxide (Trisenox), tretinoin (Vesanoid);

substances which foster anti-tumor activity; and

all substances derived from and/or related to the foregoing substances.

9. A method for determining a dose of an antineoplastic drug for a patient, comprising the steps of:

administering an initial dose of said antineoplastic drug to the patient;

examining the patient to monitor and characterize one or more numerical surrogate markers used for monitoring said antineoplastic drug;

determining if a dose change is necessary; and

calculating a revised dose as a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.

10. A method for calculating a revised dose of an antineoplastic drug for a patient, comprising the steps of:

accepting as input the patient'"'"'s current antineoplastic drug dose;

accepting as input the maximum dose of the antineoplastic drug;

accepting as input the percent response of the patient based on surrogate markers for monitoring said antineoplastic drug; and

calculating a revised dose, wherein said revised dose is a function of said current dose, said maximum dose, and said percent response of the patient based on said surrogate markers.

11. A method for calculating a revised dose of an antineoplastic drug for a patient, comprising the steps of:

accepting as input a patient'"'"'s current antineoplastic drug dose;

accepting as input a maximum dose of the antineoplastic drug;

accepting as input the previous, current and desired values of one or more numerical markers indicating the response of the patient to said antineoplastic drug;

calculating a revised dose, wherein said revised dose is a function of said current dose, said maximum dose, and said previous, current and desired values of said numerical markers.

12. A storage device having stored thereon an ordered set of instructions which, when executed by a computer, performs a predetermined method, comprising:

first means for accepting as input a patient'"'"'s current antineoplastic drug dose;

second means for accepting as input a maximum dose of the antineoplastic drug;

third means for accepting as input a percent response of a patient based on

surrogate markers for monitoring said antineoplastic drug; and

fourth means for calculating a revised dose, wherein said revised dose is a function of said current dose minus the ratio of a percent response of the patient and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.

13. The storage device of claim 12, wherein:

said antineoplastic drug is selected from a group comprising;

chemotherapeutic agents;

drugs which have an antineoplastic effect, but which are not normally classified as chemotherapeutic agents including, warfarin, heparin, minocycline, Vioxx, Celebrex, etc.;

drugs which have an antineoplastic effect that are currently in Phase I, II and/or III trials;

epothilones, analogs of epothilones, and their class of compounds;

meiphalan (Alkeran), carmustine {BCNU} (BiCNU), busulfan (Busulfex), lomustine {CCNU} (CeeNU), cyclophosphamide (Cytoxan), dacarbazine (DTIC-Dome), polifeprosan 20 with carmustine implant (Giladel), sterile ifosfamide (Ifex), chlorambucil (Leuderan), mechlorethamine (Mustargen), busulfan (Myleran), cyclophosphamide (Neosar), carboplatin (Paraplatin), cisplatin (Platinol), thiotepa (Thioplex), capecitabine (Xeloda), streptozocin (Zanosar), bicalutamide (Casodex), flutamide (Eulexin), leuprolide acetate (Lupron), nilutamide (Nilandron), leuprolide acetate (Viadur), doxorubicin hydrochloride (Adriamycin), bleomycin sulfate (Blenoxane), daunorubicin hydrochloride (Cerubidine), dactinomycin (Cosmegen), daunorubicin citrate liposome injection (DaunoXome), doxorubicin hydrochloride liposome injection (Doxil), epirubicin hydrochloride (Ellence), idarubicin hydrochloride (Idamycin), mitomycin (Mutamycin) doxorubicin (Rubex), valrubicin (Valstar), anastrozole (Arimidex), toremifene citrate (nolvadex), fluorouracil (Adrucil), cytarabine (Cyttosar-U), fluorouracil (Efudex), fludarabine (Fludara), (Fluorouracil), floxuridine (FUDR), interferon alfa-2b, recombinant (Intron A), Immunex (Methotrexate), plicamycin (Mithracin), mercaptopurine (Purinethol), methotrexate (Rheumatrex), interferon alfa-2a, recombinant (Roferon-A (Thioguanine), medroxyprogersterone acetate (Depo-Provera), estramustine phosphate sodium (Emcyt), estradiol (Estrace), leuprolide acetate (Lupron), megestrol acetate (Megace), octreotide acetate (Sandostatin), octreotide acetate for injection suspension (Sandostatin LAR), diethylstilbestrol diphosphate (Stilphostrol), testolactone (Teslac), goserelin acetate (Zoladex), etoposide phosphate (Etopophos), vincristine sulfate (Oncovin), etoposide (Toposar), vinblastine (Velban), etoposide (VePesid), vincristine sulfate (Vincasar PFS), teniposide (Vumon), trastuzumab (Herceptin), gemtuzumab ozogamicin (Mylotarg), rituximab (Rituxan), exemestane (Aromasin), irinotecan hydrocholoride (Camptosar), asparaginase (Elspar), gemcitabine hydrochloride (Gemzar), altretamine (Hexalen), topotecan hydrochloride (Hycamtin), hydroxyurea (Hydrea), (Leucovorin calcium), cladribine (Leustatin), mitotate (Lysodren) procarbazine hydrochloride, (Matulane), vinorelbine tartrate (Navelbine), pentrostatin sodium (Nipent), mitoxantrone (Novantrone), pegaspargase (Oncaspar), denileukin diftitix (Ontak), altretinoin (Panretin), porfimer (Photofrin), bexarotene (Targretin, bexarotene (Targretin Gel), paclitaxel (Taxol), docetaxel (Taxotere), temozolomide (Temodar), bacillus of Calmette and Guerin (Theracys BCG Live), arsenic trioxide (Trisenox), tretinoin (Vesanoid);

substances which foster anti-tumor activity; and

all substances derived from and/or related to the foregoing substances.

14. A storage device having stored thereon an ordered set of instructions which, when executed by a computer, performs a predetermined method, comprising:

first means for accepting as input the patient'"'"'s current antineoplastic drug dose;

second means for accepting as input the maximum dose of the antineoplastic drug;

third means for accepting as input one or more numerical markers indicating the response of the patient to said antineoplastic drug; and

fourth means for calculating a revised dose, wherein said revised dose is a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.

15. An apparatus for calculating a revised dose of an antineoplastic drug for a patient, comprising:

first means for accepting as input one or more markers which indicate a patient'"'"'s response to a dose of said antineoplastic drug;

second means for accepting as input the patient'"'"'s current antineoplastic drug dose;

third means for accepting as input the maximum dose of the antineoplastic drug; and

fourth means for calculating a revised dose of the antineoplastic drug as a function of said markers, said current antineoplastic drug dose, and said maximum antineoplastic drug dose.

16. The apparatus of claim 15, wherein:

said markers are actual numerical markers.

17. The apparatus of claim 15, wherein:

said markers are surrogate markers representing a percent response of the patient to the antineoplastic drug.

18. The apparatus of claim 15, wherein:

said revised dose is calculated by the following equation;

19. The apparatus of claim 15, wherein:

said revised dose is calculated by the equation;

20. The apparatus of claim 15, wherein:

said antineoplastic drug is selected from a group comprising;

chemotherapeutic agents;

drugs which have an antineoplastic effect, but which are not normally classified as chemotherapeutic agents including, warfarin, heparin, minocycline, Vioxx, Celebrex, etc.;

drugs which have an antineoplastic effect that are currently in Phase I, II and/or III trials;

epothilones, analogs of epothilones, and their class of compounds;

meiphalan (Alkeran), carmustine {BCNU} (BiCNU), busulfan (Busulfex), lomustine {CCNU} (CeeNU), cyclophosphamide (Cytoxan), dacarbazine (DTIC-Dome), polifeprosan 20 with carmustine implant (Giladel), sterile ifosfamide (Ifex), chlorambucil (Leuderan), mechlorethamine (Mustargen), busulfan (Myleran), cyclophosphamide (Neosar), carboplatin (Paraplatin), cisplatin (Platinol), thiotepa (Thioplex), capecitabine (Xeloda), streptozocin (Zanosar), bicalutamide (Casodex), flutamide (Eulexin), leuprolide acetate (Lupron), nilutamide (Nilandron), leuprolide acetate (Viadur), doxorubicin hydrochloride (Adriamycin), bleomycin sulfate (Blenoxane), daunorubicin hydrochloride (Cerubidine), dactinomycin (Cosmegen), daunorubicin citrate liposome injection (DaunoXome), doxorubicin hydrochloride liposome injection (Doxil), epirubicin hydrochloride (Ellence), idarubicin hydrochloride (Idamycin), mitomycin (Mutamycin) doxorubicin (Rubex), valrubicin (Valstar), anastrozole (Arimidex), toremifene citrate (nolvadex), fluorouracil (Adrucil), cytarabine (Cyttosar-U), fluorouracil (Efudex), fludarabine (Fludara), (Fluorouracil), floxuridine (FUDR), interferon alfa-2b, recombinant (Intron A), Immunex (Methotrexate), plicamycin (Mithracin), mercaptopurine (Purinethol), methotrexate (Rheumatrex), interferon alfa-2a, recombinant (Roferon-A (Thioguanine), medroxyprogersterone acetate (Depo-Provera), estramustine phosphate sodium (Emcyt), estradiol (Estrace), leuprolide acetate (Lupron), megestrol acetate (Megace), octreotide acetate (Sandostatin), octreotide acetate for injection suspension (Sandostatin LAR), diethylstilbestrol diphosphate (Stilphostrol), testolactone (Teslac), goserelin acetate (Zoladex), etoposide phosphate (Etopophos), vincristine sulfate (Oncovin), etoposide (Toposar), vinblastine (Velban), etoposide (VePesid), vincristine sulfate (Vincasar PFS), teniposide (Vumon), trastuzumab (Herceptin), gemtuzumab ozogamicin (Mylotarg), rituximab (Rituxan), exemestane (Aromasin), irinotecan hydrocholoride (Camptosar), asparaginase (Elspar), gemcitabine hydrochloride (Gemzar), altretamine (Hexalen), topotecan hydrochloride (Hycamtin), hydroxyurea (Hydrea), (Leucovorin calcium), cladribine (Leustatin), mitotate (Lysodren) procarbazine hydrochloride, (Matulane), vinorelbine tartrate (Navelbine), pentrostatin sodium (Nipent), mitoxantrone (Novantrone), pegaspargase (Oncaspar), denileukin diftitix (Ontak), altretinoin (Panretin), porfimer (Photofrin), bexarotene (Targretin, bexarotene (Targretin Gel), paclitaxel (Taxol), docetaxel (Taxotere), temozolomide (Temodar), bacillus of Calmette and Guerin (Theracys BCG Live), arsenic trioxide (Trisenox), tretinoin (Vesanoid);

substances which foster anti-tumor activity; and

all substances derived from and/or related to the foregoing substances.